Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Curr Infect Dis Rep. 2010 Jul;12(4):253-6. doi: 10.1007/s11908-010-0115-2.
Recently, interest has emerged regarding adjuvant antiplatelet therapy in infective endocarditis (IE) and its impact on clinical outcomes. Despite ongoing research, the role of antiplatelet therapy in this setting remains unclear. Generally, investigations of IE are limited by the low incidence of the disease, practical issues related to diagnosis, and the highly variable latency period between symptom onset and definitive diagnosis. This article reviews the rationale for using antiplatelet therapy in the setting of IE and the contemporary literature that investigates its use.
最近，人们对感染性心内膜炎（IE）中的辅助抗血小板治疗及其对临床结果的影响产生了兴趣。尽管在不断进行研究，但在这种情况下抗血小板治疗的作用仍不明确。一般来说，IE 的研究受到疾病发生率低、与诊断相关的实际问题以及症状发作和明确诊断之间潜伏期差异很大的限制。本文综述了在 IE 情况下使用抗血小板治疗的原理以及研究其使用的当代文献。
